We’re thrilled by the overwhelming response to Wesley Research Institute’s Coeliac Disease Webinar held on August 27th. The strong interest reflects a growing eagerness to better understand the latest research and treatment developments for coeliac disease.
Over 100 participants tuned in to the session, which delivered valuable insights into the prevalence of coeliac disease among first-degree relatives, advancements in paediatric gastroenterology, and a global overview of emerging therapeutic approaches.
Our sincere appreciation goes to our supporters of this webinar, the Rosalie Martin Event Series, as well as our guest speakers, Dr Richard Muir and Dr Paul Wagner.
Watch Webinar
Watch the Coeliac Disease Webinar recording here – https://youtu.be/mxeIhUiW3Bw
Key insights from listening to Dr Richard Muir and Dr Paul Wagner:
The Genetic Link: Individuals with coeliac disease should be aware that their first-degree relatives have a 7–11% risk of also having the condition, compared to just 0.7% in the general population. For identical twins, this risk increases dramatically to 80%. Alarmingly, around 80% of people with coeliac disease remain undiagnosed— and one-third present with no symptoms at the time of diagnosis.
A Systemic Condition – Not Just Gut-Related: Coeliac disease has widespread health implications. In children, it can lead to impaired growth, delayed puberty, and reduced bone density. Adults may experience fertility challenges, a heightened risk of autoimmune disorders (e.g. 4% for thyroid disease vs. 0.5% in the general population), and, in severe cases, an increased cancer risk if intestinal damage persists.
Current Treatment Limitations: A strict gluten-free diet is the standard treatment for coeliacs, but for many, it’s not enough. Even minimal gluten exposure through sources like shared kitchen equipment, paper straws, or hidden ingredients in sauces can cause ongoing symptoms and significantly affect quality of life. This highlights the urgent need for additional treatment options.
Promising Advances: Targeted immunomodulators have shown encouraging results in Phase 1B trials, including a 42% reduction in symptoms and significant protection against intestinal damage during controlled gluten exposure. Several emerging therapies are in the pipeline, offering hope for better protection and improved quality of life.
Recommended Actions for Families: Routine coeliac disease screening for first-degree relatives every four years, particularly during key growth phases in children, could lead to earlier detection and better outcomes. HLA genetic testing may also help identify those who should be monitored more closely over time.
Stay Engaged
Wesley Research Institute is committed to keeping the coeliac community informed and engaged.
“We encourage anyone interested to follow our research, participate in trials and stay up to date with new developments through our Coeliac Research Network,” Dr Daveson said.
Learn more about our Coeliac Disease and Immune Health Research Program, or if you haven’t already become an active member of our Coeliac Research Network.
Stay tuned for future webinars and research updates as the journey towards better treatments for coeliac disease continues. Don’t miss out, sign up for the next webinar.